Subject Index

Acute kidney injury (AKI)
  continuous renal replacement therapy, see Continuous renal replacement therapy
diagnosis 126, 127
electronic alert systems
evaluation 128
output 127
overview 124–126
prospects 128
ADVANCE study 175
Advanced carbohydrate counting, see Carbohydrate counting
AKI, see Acute kidney injury
Anemia
  erythropoiesis-stimulating agent therapy
    concerns 185, 186
    peginesatide 186
    prospects 187
  hypoxia-inducible factor stabilizer
    therapy 186, 187
  overview in chronic kidney disease 184, 185
Arteriovenous fistula, see Vascular access
Arteriovenous graft, see Vascular access
ATA membrane dialyzer
  commercial products 219
cross-sectional structure 216
development 215
diffusion performance 217, 218
filtration properties 216, 217
material properties 215, 216
protein adsorption 218, 219
smoothness 218
sterilization 220
BalANZ trial 92, 93, 95, 97
Basic carbohydrate counting, see Carbohydrate counting
Bisphosphonates, vascular calcification prevention 175
Calcimimetics, vascular calcification prevention 175
Cambodia
dialysis history 110
financial problems 111, 112
medical equipment and drugs 111
medical training 111
vascular access 112, 113
CAPD, see Continuous ambulatory peritoneal dialysis
Carbohydrate counting, glycemic control in diabetic hemodialysis
  advanced carbohydrate counting 264
  basic carbohydrate counting
    dietician-led instruction 263, 264
    energy requirement determination 263
    physician-led instruction 263
    basic versus advanced counting 263
    efficacy studies 264–268
    overview 262, 263
Catheter, see Peritoneal dialysis; Vascular access
CAVH, see Continuous arteriovenous hemofiltration
Central venous catheter, see Vascular access
Clear space (CS)
  advantages 202
  clinical application 199–201
  theory 198, 199
Clearance gap, see Vascular access
Continuous ambulatory peritoneal dialysis (CAPD)
automated peritoneal dialysis 90
biocompatible solutions
adverse event impact 98, 99
costs 97
inflow pain reduction 96, 97
lipid profile 97
overview of advantages 91, 92
peritoneal membrane function 93–95
peritonitis rates 95
prospects 99
residual renal function preservation 92, 93
technique and patient survival 97, 98
historical perspective 85–89
molecule transport characteristics 89
Oreopoulos technique 88, 89
uremia 89, 90
Continuous arteriovenous hemofiltration (CAVH), historical perspective 115
Continuous renal replacement therapy (CRRT)
connectivity 120
continuous arteriovenous hemofiltration 115
dedicated equipment 116
evolution of techniques 116
hemodiafiltration 115
multiple organ support therapy 116, 117
overview 114, 115
pediatrics 121
requirements 117–120
ultrafiltration 115
venovenous pumped techniques 115, 116
CONTRAST study 3–5, 11, 31, 32, 193, 194
Convective dose, see On-line hemodiafiltration
CorDix filters
overview 237, 238
patient characteristics for evaluation 238
renal replacement performance 240–243
solute clearance 243, 244
study design for evaluation 238–240
CRRT, see Continuous renal replacement therapy
CS, see Clear space
Denosumab, vascular calcification prevention 175
Diabetes, see Carbohydrate counting
Dialysis fluid
endotoxin-retentive filter management 158
quality standards
on-line prepared substitution fluid 155
overview 153, 154
standard fluid 154, 155
toxic chemicals
limits 155, 156
monitoring frequency 156, 157
ultrapure fluid 155
water quality 154
Southeast Asia
dialysate quality 104–106
Japan support of dialysate purification with technical support 105, 107, 108
treatment equipment
management 157
safety management committee 158, 159
Dialysis Outcomes and Practice Pattern Study (DOPPS) 3, 7, 10
Dialyzer, see also specific dialyzers
biocompatibility
azotemic toxic clearance 133–135
complications of incompatibility 211
factors affecting 211
polymer types 138, 139
uremic solute clearance 132, 133
design
membrane types and materials 204–206
optimization 208
performance 206–208
environmental considerations 135
protein adsorption 139, 140
requirements 208
time degradation 208
water structure of polymers 140–142
DIUREST study 92
DOPPS, see Dialysis Outcomes and Practice Pattern Study
EDOIDEA study 22
Erythropoiesis-stimulating agents, see Anemia
ESHOL study 3, 5, 12, 193, 194
Extracorporeal circuit, design and biocompatibility 131, 132
Fibrosis, see Renal fibrosis
Glycemic control, see Carbohydrate counting

HDF, see Hemodiafiltration

HEMO Study 2

Hemodiafiltration (HDF), see also Intermittent infusion hemodiafiltration; On-line hemodiafiltration

acceptance barriers 34
adequacy barriers 32, 33
albumin-permeable hemodiafiltration 193, 194
biocompatibility
  blood cell-polymer interactions 211
  dilution methods and oxidative stress 211–213
  microinflammation improvement 211, 214
costs 33
historical perspective 115
key requirements 33, 34
safety 30–32

Hemodialysis, see also High-flux hemodialysis;
  Home hemodialysis; specific countries

albumin-permeable hemodialysis 191, 192
Cambodia 110–113
intensive hemodialysis
  clinical value 37, 39
  home hemodialysis
    comparison to in-center 39, 40
    challenges 40–43
    prospects 43
Korea
  end-stage renal disease epidemiology and etiology 65, 66
  National Health Insurance System 66
  survival 66–69
peritoneal dialysis comparison, see Peritoneal dialysis

South Asia
  chronic kidney disease epidemiology 71, 72
  peritoneal dialysis advantages over hemodialysis
    cardiovascular mortality 76, 77
    dialysis center lack 76
    hepatitis prevention 76
    nutrition status 76
    renal replacement therapy status 73

  socioeconomic challenges 72, 77

  Southeast Asia
    dialysate quality 104–106
    dialysis services status 103, 104
  Japan support of developing countries
    dialysate purification technical support 105, 107, 108
    overview 102, 103
  survival 37, 38

  Hepatitis, prevention with peritoneal dialysis 76
  hf-HD, see High-flux hemodialysis
  HHD, see Home hemodialysis
  HIF, see Hypoxia-inducible factor

  High-flux hemodialysis (hf-HD), clinical studies 2

  Home hemodialysis (HHD)
    equipment 49–51
    intensive hemodialysis
      challenges 40–43
      clinical value 37, 39
      comparison to in-center 39, 40
      prospects 43

  Japan
    dose 56, 57
    patient characteristics 55, 56
    popularity 54, 55
    prospects for study 59
    socioeconomic status 57–59
    overview 46, 47
    patient selection 47–49
    support 52
    training 48, 49
    vascular access 51

  Hyperphosphatemia, prevention
    binders 173, 174
    dietary phosphate restriction 173
    renal replacement therapy 171–173

  Hypoxia-inducible factor (HIF), stabilizers 186, 187

  I-HDF, see Intermittent infusion hemodiafiltration

  India, peritoneal dialysis 73, 74

  Intermittent infusion hemodiafiltration (I-HDF)
    overview 24, 25
    predilution on-line hemodiafiltration
      comparison
        blood parameters 26–28
Subject Index

patient selection 28, 29
quality of life 26
study design 25, 26

Japan
glycemic control in diabetic hemodialysis
patients with carbohydrate counting
advanced carbohydrate counting 264
basic carbohydrate counting
dietician-led instruction 263, 264
ergy requirement
determination 263
physician-led instruction 263
basic versus advanced counting 263
efficacy studies 264–268
overview 262, 263

health care system
economy overview and health care expenditure 258–260

efficiency 260

hemodialysis costs
medical economics 260, 261
overview 257, 258

home hemodialysis
dose 56, 57
patient characteristics 55, 56
popularity 54, 55
prospects for study 59
socioeconomic status 57–59

on-line hemodiafiltration
predilution on-line hemodiafiltration 18, 19

trends 18

support of developing countries in Southeast Asia
dialysate purification technical support 105, 107, 108

overview 102, 103

Klotho
epigeneics in expression regulation 182
organ protection 179, 180

Korea, peritoneal dialysis
end-stage renal disease epidemiology and etiology 65, 66
National Health Insurance System 66
survival 66–69

Kt/V 197, 198

Low-molecular-weight proteins, see
β2-Microglobulin

β2-Microglobulin
albumin-permeable hemodiafiltration 193, 194
albumin-permeable hemodialysis 191, 192
low-molecular-weight proteins
microglobulin as marker 190
types 189, 190
mortality impact in hemodialysis
patients 190, 191
on-line hemodiafiltration studies 4
removal along with albumin 191

MicroRNA
oncology markers 160, 161
therapeutic targeting 166
vascular calcification in chronic kidney disease
miR-126 in endothelial dysfunction 163–166
overview 161–163

MPO Study 2

NF dialyzer
adsorbed protein
quantification 233
structure 232
clinical trials 234, 235
design 231, 232
leukocyte activation 233
overview 230, 231
platelet adhesion 232.233

NV dialyzer
antithrombotic properties 224, 225
clinical evaluation 226–228
polyvinylpyrrolidone thrombogenicity 223
rationale for development 222, 223

OL-HDF, see On-line hemodiafiltration

On-line hemodiafiltration (OL-HDF)
anemia, phosphate, and β2-microglobulin
studies 4
cardiocirculatory stability studies 2, 3
convective dose
definition and role in dialysis adequacy 10
factors affecting 14, 15
minimal versus optimal dose 10–12
optimal versus individualized dose 12–14
cost 6
fluid replacement rate and survival 4–6
Japan trends 18
predilution on-line hemodiafiltration
   advantages 19, 20, 22
   clinical trials 20–22
   intermittent infusion hemodiafiltration
      comparison
         blood parameters 26–28
         patient selection 28, 29
         quality of life 26
         study design 25, 26
Japan 18, 19
prospects for study 6, 7, 15
safety 6
survival studies 3, 4
Oxidative stress
   DNA damage 178, 179
   hemodiafiltration dilution method
      impact 211–213
Parathyroidectomy, vascular calcification
   prevention 174, 175
PD, see Peritoneal dialysis
Peginesatide 186
Peritoneal dialysis (PD), see also Continuous
   ambulatory peritoneal dialysis
catheter insertion
   overview 80
   nephrologist-initiated program 80–82
   cumulative summation charting as
      monitoring tool 82, 83
hemodialysis comparison in United States
   adequacy 63
   frequency and patient
      characteristics 61–63
   prospects 63, 64
Korea
   end-stage renal disease epidemiology and
      etiology 65, 66
   National Health Insurance System 66
   survival 66–69
South Asia
   advantages over hemodialysis
      cardiovascular mortality 76, 77
      dialysis center lack 76
   hepatitis prevention 76
   nutrition status 76
automated peritoneal dialysis 75
chronic kidney disease epidemiology 71, 72
home visits 74
India 73, 74
industry role 73, 74
insurance 74
kidney transplant patients 75, 76
Once-in-a-Life Time Payment Scheme 74
renal replacement therapy status 73
socioeconomic challenges 72, 77
teledicine 74
Predilution on-line hemodiafiltration, see
On-line hemodiafiltration
QCM, see Quartz crystal microbalance
Quartz crystal microbalance (QCM) 139, 140
Renal fibrosis
   histone methyltransferase inhibitor
      therapy 181, 182
   Klotho studies
      epigenetics in expression regulation 182
      protective role 179, 180
   oxidative stress and DNA damage 178, 179
   therapeutic targets 180, 181
   transforming growth factor-β/Smad
      signaling 181
RISCAVID study 11
Socioeconomic status
   Japan home hemodialysis patients 57–59
   South Asia chronic kidney disease
      patients 72, 77
   TGF-β, see Transforming growth factor-β
   Transforming growth factor-β (TGF-β), renal
      fibrosis role 181
   TRIO trial 93
Ubiquitous Blood Purification International
   (UBPI) 102, 108, 111
UBPI, see Ubiquitous Blood Purification
   International
Ultrafiltration, fluid balance control 115
VA, see Vascular access

Vascular access (VA)

arteriovenous fistula 253, 254
arteriovenous graft 254, 255
Cambodia 112, 113

catheter, titanium-doped hydroxyapatite nanoparticle coating
antibacterial activity 145, 146, 148, 150, 151
characterization 145–147
coated sheet preparation 146
materials 145
nanoparticle distribution and coating 147, 148
nanoparticle preparation 145
overview 144, 145

central venous catheter 255
clearance gap
clinical findings 247, 248
clinical markers 248–250
effective versus theoretical clearance 247

dietary phosphate restriction 173

denosumab 175
endothelial calcification 171
hyperphosphatemia prevention
binders 173, 174
dietary phosphate restriction 173
renal replacement therapy 171–173
medial calcification 171
parathyroidectomy 174, 175
prospects 176
vitamin K 175

risk factors
endothelial calcification 170
medial calcification 170, 171
types of calcification 169, 170

Vitamin K, vascular calcification prevention 175

Vascular calcification, chronic kidney disease

microRNA studies
miR-126 in endothelial dysfunction 163–166
overview 161–163
therapeutic targeting 166

prevention
bisphosphonates 175
calcimimetics 175
denosumab 175
endothelial calcification 171
hyperphosphatemia prevention
binders 173, 174
dietary phosphate restriction 173
renal replacement therapy 171–173
medial calcification 171
parathyroidectomy 174, 175
prospects 176
vitamin K 175

risk factors
endothelial calcification 170
medial calcification 170, 171
types of calcification 169, 170

Vitamin K, vascular calcification prevention 175